In line with Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, AstraZeneca Pharma India has informed that it enclosed the press release for the quarter ended June 30, 2026. The company has informed that the phrase ‘Profit after exceptional item and tax’ appearing in the financial performance summary is to be read as ‘Profit after exceptional item and before tax’ (i.e. Profit before tax).
The above information is a part of company’s filings submitted to BSE.
